In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole

Josep M. Torres-Rodríguez, Raúl Mendez, Olga López-Jodra, Yolanda Morera, Mateu Espasa, Teresa Jimenez, Carme Lagunas

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)

Abstract

The antifungal activity of eberconazole, a new imidazole derivative, against 124 clinical isolates of Candida comprising eight different species and to 34 isolates of Cryptococcus neoformans was compared to those od clotrimazole and ketoconazole. MICs of eberconazole, determined by the National Committee for Clinical Laboratory Standards standardized microbroth method, were equal to or lower than those of other azoles, especially for Candida krusei and Candida glabrata, which are usually resistant to triazoles.
Original languageEnglish
Pages (from-to)1258-1259
JournalAntimicrobial Agents and Chemotherapy
Volume43
Issue number5
Publication statusPublished - 1 May 1999

Fingerprint Dive into the research topics of 'In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole'. Together they form a unique fingerprint.

Cite this